Related Experiment Videos
Summary
Antifungal therapy advanced significantly after 1950, with polyenes and amphotericin B introduced in the 1950s, followed by 5-fluorocytosine and imidazoles twenty years later.
Area of Science:
- Medical Mycology
- Pharmacology
- Infectious Diseases
Background:
- Limited effective treatments for systemic and invasive mycoses existed before 1950.
- Traditional topical treatments were used for dermatomycoses.
- The rise of opportunistic fungal infections created a need for new antifungal agents.
Purpose of the Study:
- To review the historical development of antifungal therapies.
- To highlight key advancements in the treatment of fungal infections.
Main Methods:
- Historical review of antifungal drug development.
- Analysis of therapeutic introductions and their impact.
Main Results:
- The 1950s saw the introduction of polyenes (nystatin, pimaricin) and amphotericin B.
- Twenty years later, 5-fluorocytosine and imidazole derivatives became clinically available.
- These advancements provided crucial options for treating candidiasis and severe systemic mycoses.
Conclusions:
- Two distinct eras of progress revolutionized antifungal therapy.
- Newer agents addressed the increasing challenge of iatrogenic mycoses.
- These developments significantly improved patient outcomes for fungal infections.